Delisting threat looms large on biotech front

Article Abstract:

The first three quarters of the year 2004 reported that delistings of about 52 stocks and 70 companies against 193 companies in the year 2003.Poor market performance is partly responsible for a large number of biotech companies being delisted along with the companies who do not have products advanced enough to sustain investor's interest over long periods of time.

---

Making it in the biotech business

Article Abstract:

The biotech is big business and record numbers of PhDs are trading the ivory tower for industry in which being good at research is not enough for success in the biotech business. The Biotechnology Industry Organization, revealed that 1500-biotech companies in the United States have combined revenues exceeding $40 billion.

---

When less is more

Article Abstract:

Studies have shown that the biotech companies receiving the most financing are not necessarily delivering the best returns.

Return on investment, Rate of return

Similar abstracts:

• Abstracts: US to safeguard 'dual-use' biology research. When less is more
• Abstracts: Robbing Peter to pay Paul. Biotechs for pennies? Bargains in the basement
• Abstracts: Adaptation to culture of human embryonic stem cells and oncogenesis in vivo. Recurrent gain of chromosomes 17q and 12 in cultured human embryonic stem cells
• Abstracts: Dogsters Healthy Treats Ice Crunchie Frozen Ice Pops. Dogsters Healthy Treats Yogurt Combos Frozen Yogurt
• Abstracts: D.L. Jardine's Texas Ranch Recipes Bronco Mustard. French's Classic Yellow Mustard. French's Mustard

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.